(R)-2-amino-7-(2-bromo-4-methoxy-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: (R)-2-amino-7-(2-bromo-4-methoxy-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
• 英文别名: (7R)-2-amino-7-(2-bromo-4-methoxyphenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
• 化学式: C₁₅H₁₅BrN₄O₂
• 分子量: 363.214
• InChiKey: AGPPCVBZLSKPFP-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  90.1
• 氢给体数：
  2
• 氢受体数：
  5

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(R)-2-amino-7-[4-methoxy-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one	——	C21H21N5O3	391.429

反应信息

• 作为反应物：
  描述：

  (R)-2-amino-7-(2-bromo-4-methoxy-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one 、 6-甲氧基吡啶-2-硼酸频哪醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 19.0h， 生成 (R)-2-amino-7-[4-methoxy-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
  参考文献：
  名称：

  Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990

  摘要：

  Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.

  DOI：

  10.1021/jm501107q
• 作为产物：
  描述：

  2-溴-4-甲氧基苯甲醛 在 四氢吡咯 、 盐酸 、 titanium(IV) tetraethanolate 、 sodium methylate 、 三乙胺 、 copper(l) chloride 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 63.33h， 生成 (R)-2-amino-7-(2-bromo-4-methoxy-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
  参考文献：
  名称：

  Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990

  摘要：

  Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.

  DOI：

  10.1021/jm501107q

文献信息

• 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones
  申请人：Machajewski D. Timothy

  公开号：US20070123546A1

  公开（公告）日：2007-05-31

  Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

  本发明公开了2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物及其立体异构体、互变异构体、药学上可接受的盐和前药；包括药学上可接受的载体和一种或多种2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物的组合物，单独或与至少一种其他治疗剂联合使用的组合物；以及使用2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物，单独或与至少一种其他治疗剂联合使用，在细胞增殖、病毒、自身免疫、心血管和中枢神经系统疾病的预防或治疗中的方法。
• 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones
  申请人：Machakewski Timothy D.

  公开号：US20100004237A1

  公开（公告）日：2010-01-07

  Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

  本发明涉及2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物及其立体异构体、互变异构体、药学上可接受的盐和前药；包括药学上可接受的载体和一种或多种2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物的组合物，单独使用或与至少一种其他治疗剂联合使用的组合物；以及使用单独使用或与至少一种其他治疗剂联合使用的2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物预防或治疗细胞增殖、病毒、自身免疫、心血管和中枢神经系统疾病的方法。
• EP1928875B1
  申请人：——

  公开号：EP1928875B1

  公开（公告）日：2011-06-29
• US7671059B2
  申请人：——

  公开号：US7671059B2

  公开（公告）日：2010-03-02
• [EN] 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES<br/>[FR] 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDINE-5-ONES
  申请人：NOVARTIS AG

  公开号：WO2007041362A1

  公开（公告）日：2007-04-12

  [EN] Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nevous system diseases.
  [FR] L'invention concerne des composés de 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidine-5-one, leurs stéréoisomères, des tautomères, des sels pharmaceutiquement acceptables et des promédicaments de ceux-ci ; des compositions qui comprennent un support pharmaceutiquement acceptable et un ou plusieurs des composés de 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidine-5-one, soit seuls, soit en combinaison avec un ou plusieurs agents thérapeutiques supplémentaires. L'invention présente aussi des procédés utilisant les composés de 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidine-5-one, soit seuls, soit en combinaison avec un ou plusieurs agents thérapeutiques supplémentaires, dans la prophylaxie ou le traitement de maladies à prolifération cellulaire, virales, autoimmunes, cardiovasculaires et du système nerveux central.